Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06010355 | Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable Communities | terminated | N/A | 11 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06026332 | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting(ABLE-41) | terminated | — | 202 | Ferring PharmaceuticalsINDUSTRY | 1 | Feb 17, 2026 |
| NCT04328714 | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease | terminated | Phase 1 | 4 | Edwin HorwitzOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03913559 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | terminated | Phase 2 | 5 | St. Jude Children's Research HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04504331 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | terminated | Phase 1 | 4 | Jennifer Lee Caswell-JinOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05654779 | CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 4 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | terminated | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03237572 | Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer(Breast-48) | terminated | Phase 1 | 13 | Patrick Dillon, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma(TEM-GU) | terminated | Phase 1 / Phase 2 | 10 | Genenta ScienceINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02724202 | Curcumin in Combination With 5FU for Colon Cancer | terminated | Early Phase 1 | 15 | Baylor Research InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05443971 | Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01795313 | Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod | terminated | Phase 1 | 23 | James FelkerOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | terminated | Phase 1 | 16 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04990895 | A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys | terminated | N/A | 8 | AHS Cancer Control AlbertaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | terminated | Early Phase 1 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05489250 | The PLATON Network(PLATON) | terminated | — | 565 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | terminated | Phase 1 / Phase 2 | 2 | Ariceum Therapeutics GmbHINDUSTRY | 2 | Feb 5, 2026 | clinicaltrials |
| NCT04166734 | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma(MESO-PRIME) | terminated | Phase 1 | 5 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)(topMIND) | terminated | Phase 1 / Phase 2 | 54 | Incyte CorporationINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04889989 | Microwave Ablation in Chinese Patients With Lung Tumors | terminated | N/A | 13 | Ethicon, Inc.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | terminated | Phase 1 / Phase 2 | 46 | SanofiINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT04044872 | Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity | terminated | Early Phase 1 | 3 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | terminated | N/A | 7 | National Institutes of Health Clinical Center (CC)NIH | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | terminated | Phase 2 | 5 | Replimune, Inc.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02886546 | Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy | terminated | N/A | 26 | Hallym University Kangnam Sacred Heart HospitalOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT03323944 | CAR T Cell Immunotherapy for Pancreatic Cancer | terminated | Phase 1 | 54 | University of PennsylvaniaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care | terminated | Phase 2 | 3 | Johns Hopkins UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma(iinnovate-3) | terminated | Phase 1 / Phase 2 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 7 | Jan 30, 2026 | clinicaltrials |
| NCT05814666 | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC(PEMDA-HN) | terminated | Phase 2 | 69 | Flamingo Therapeutics NVINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT06654245 | Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors(SHAREDCare) | terminated | N/A | 5 | Wake Forest University Health SciencesOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT03436056 | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients(PRIMING) | terminated | Phase 1 | 2 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03957551 | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 28 | John RiethOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 45 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT04557007 | Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients(Oncomabs) | terminated | — | 80 | Oslo University HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Mamta ParikhOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma(iinnovate-2) | terminated | Phase 1 | 15 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 4 | Jan 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 17, 2026source: clinicaltrials